Good call Mozz. A lot of focus has been on the science which makes sense as that's where the FDA approval will be based on. This however has created a blind spot to the lack of evidence to the CEO's inability to do a deal or even secure a strategic investor.
Not being wise after the fact it os something I have raised numerous times on HC.
Retail holders at the AGM need to put a torch to fiddling around on securing a partnership deal. Enough is enough.
Ann: PAR Successful Placement and Fully Underwritten ANREO, page-76
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |